Chandra Bhagat PharmaShare price, financial results, shareholding and management
- Market cap
- ₹50 cr
- Stock P/E
- 16.3peers 19.8
- Book value
- ₹45.1
- Price to book
- 1.46
- EV / operating profit
- -
- Market cap to sales
- 0.43
- ROCE · FY26
- 12.0%
- ROE · FY26
- 9.5%
- ROE, 3-year average
- 5.9%
- Operating margin · FY26
- 3.3%peers 16.5%
- Sales growth, 3 years
- -1.0%
- Profit growth, 3 years
- 49.7%
- Debt to equity
- 0.50peers 0.35
- Borrowings
- ₹17 cr
- Interest cover
- 3.1×
- Cash from business / op. profit
- 234%
- Debtor days
- 171
- Pledged
- 0.00%
- Promoter holding
- 73.02%
- Change in promoter holding
- +0.83 pts
- Shareholders
- 280
- 52-week high / low
- ₹73 / ₹30
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.
Chandra Bhagat Pharma share price chart
Close on 19 Nov 2026 · -4.98% on the day · Vol 18,000
Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 19 Nov 2026
- 1 month
- +65.0%
- 3 months
- +32.2%
- 6 months
- +81.8%
- 1 year
- +65.2%
- Traded a day, 20 days
- ₹0.03 cr
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +34% | +255% |
| 3 years, a year | -1% | +50% |
| Latest half, H2 FY26 | +316% | +1429% |
Chandra Bhagat Pharma revenue and profit growth
Half-yearly results · Profit and lossSales have fallen. Last year profit grew faster than sales, so the company kept more from each rupee of sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.
Chandra Bhagat Pharma half-yearly results
SME companies report every six months · ₹ crore
| H1FY23 | H2FY23 | H1FY24 | H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 44.27 | 75.40 | 119.26 | 102.11 | 64.92 | 21.80 | 25.55 | 90.73 |
| Expenses | 43.25 | 73.60 | 124.26 | 104.15 | 66.12 | 22.06 | 24.18 | 88.54 |
| Operating profit | 1.03 | 1.80 | -5 | -2.04 | -1.20 | -0.26 | 1.37 | 2.19 |
| OPM | 2.3% | 2.4% | -4.2% | -2.0% | -1.9% | -1.2% | 5.4% | 2.4% |
| Interest | 1.04 | 1.15 | 0.66 | 0.73 | 0.85 | 1.10 | 0.81 | 1.19 |
| Depreciation | 0.05 | 0.22 | 0.43 | 0.21 | 0.41 | 0.54 | 0.61 | 0.49 |
| Profit before tax | 0.54 | 0.62 | 0.92 | 1.34 | 0.61 | 0.55 | 0.29 | 3.52 |
| Net profit | 0.37 | 0.54 | 0.64 | 0.90 | 0.69 | 0.17 | 0.23 | 2.60 |
Chandra Bhagat Pharma profit and loss
Full years to March, FY15 to FY26 · ₹ crore, consolidated where reported
| FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 61 | 80 | 90 | 97 | 106 | 94 | 71 | 94 | 119.67 | 221.37 | 86.72 | 116.27 |
| Expenses | 58 | 76 | 85 | 92 | 102 | 91 | 67 | 91 | 116.35 | 228.41 | 88.17 | 112.42 |
| Operating profit | 3 | 3 | 4 | 5 | 5 | 3 | 4 | 3 | 3.32 | -7.04 | -1.46 | 3.85 |
| OPM | 4.9% | 4.3% | 4.9% | 4.7% | 4.3% | 3.3% | 5.0% | 3.0% | 2.8% | -3.2% | -1.7% | 3.3% |
| Other income | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0.29 | 11.33 | 5.52 | 3.35 |
| Interest | 2 | 3 | 4 | 4 | 4 | 3 | 4 | 3 | 2.19 | 1.39 | 1.95 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.27 | 0.64 | 0.95 | 1.10 |
| Exceptional and other items | · | 1 | 1 | · | · | · | · | -1 | · | · | · | · |
| Profit before tax | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 1.16 | 2.26 | 1.17 | 4.11 |
| Tax rate | 100.0% | 100.0% | 0.0% | 50.0% | 0.0% | 26.0% | 32.0% | 0.0% | 21.6% | 32.3% | 26.5% | 25.8% |
| Net profit | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0.91 | 1.53 | 0.86 | 3.05 |
| EPS ₹ | 10.29 | 8.37 | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.20 | 2.03 | 1.14 | 4.04 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
The years to FY22 come rounded to the nearest crore in the source.
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
A tax rate above 60% or below zero (FY15, FY16) comes from tax charged on a small or negative profit, as reported.
Earnings per share before FY20 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.
Chandra Bhagat Pharma profitability
Margins and returns on capitalLast year the company kept more from each rupee of sales than the year before. It earns a moderate return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | 4.9% | 4.3% | 4.9% | 4.7% | 4.3% | 3.3% | 5.0% | 3.0% | 2.8% | -3.2% | -1.7% | 3.3% |
| Tax rate | 100.0% | 100.0% | 0.0% | 50.0% | 0.0% | 26.0% | 32.0% | 0.0% | 21.6% | 32.3% | 26.5% | 25.8% |
| ROCE | · | 11.6% | 15.7% | 20.1% | 13.1% | 5.9% | 7.3% | 7.9% | 7.1% | 7.9% | 6.5% | 12.0% |
| ROE | · | 0.0% | 14.5% | 12.6% | 8.7% | 0.0% | 0.0% | 3.8% | 3.3% | 5.4% | 2.9% | 9.5% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Chandra Bhagat Pharma debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown. Its loans are smaller than its own money. Last year the business brought in more cash than it showed as profit. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Chandra Bhagat Pharma balance sheet
At each 31 March · ₹ crore
| FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 0.42 | 0.42 | 0.42 | 0.42 | 0.67 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 6 | 6 | 7 | 8 | 14 | 18 | 18 | 19 | 20 | 21 | 22 | 26 |
| Net worth | 6.42 | 6.42 | 7.42 | 8.42 | 14.67 | 26 | 26 | 27 | 28 | 29 | 30 | 34 |
| Borrowings | 28 | 28 | 22 | 22 | 31 | 30 | 27 | 21 | 19 | 16 | 21 | 17 |
| Other liabilities | 7.58 | 9.58 | 26.58 | 27.58 | 37.33 | 19 | 19 | 24 | 14 | 57 | 51 | 43 |
| Total liabilities | 42 | 44 | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 102 | 94 |
| Fixed assets | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 3 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 5 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Other assets | 41 | 43 | 50 | 56 | 79 | 74 | 72 | 72 | 60 | 99 | 99 | 89 |
Chandra Bhagat Pharma cash flow
₹ crore
| FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0 | 0 | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 6 | -6 | 9 |
| Cash from investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -1 | 0 |
| Cash from financing | 0 | 0 | 8 | 7 | -4 | 7 | -6 | -10 | -4 | -6 | 2 | -6 |
| Net cash flow | 0 | 0 | -1 | 1 | 0 | 0 | 2 | 2 | 1 | -2 | -5 | 3 |
Working capital
Days
| FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 71 | 66 | 80 | 67 | 90 | 54 | 80 | 58 | 25 | 65 | 148 | 171 |
| Inventory days | 177 | 123 | 133 | 145 | 174 | 187 | 215 | 153 | 100 | 15 | 3 | 18 |
| Days payable | 43 | 33 | 81 | 69 | 117 | 53 | 79 | 12 | 11 | 23 | 45 | 124 |
| Cash conversion cycle | 205 | 156 | 132 | 143 | 146 | 188 | 216 | 199 | 114 | 57 | 107 | 65 |
| Working capital days | 166 | 134 | 125 | 138 | 83 | 148 | 177 | 104 | 75 | 36 | 101 | 77 |
Chandra Bhagat Pharma peers and competitors
Listed SME companies in the same industryBy sales, Chandra Bhagat Pharma is number 12 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Astonea Labs | 341 | 68.1 | 148 | 5 | 9.0% | 0.74 |
| Influx Healthtech | 632 | 30.8 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 35 | 5.5 | 131 | 6.4 | 8.9% | 0.47 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Trident Lifeline | 481 | 25.3 | 129 | 19 | 22.0% | 0.73 |
| Chandra Bhagat Pharma | 50 | 16.3 | 116 | 3.1 | 3.3% | 0.50 |
| Quest Laboratories | 154 | 10.3 | 112 | 15 | 16.3% | 0.08 |
| KRM Ayurveda | 573 | 28.6 | 102 | 20 | 30.0% | 0.00 |
| Sotac Pharmaceuticals | 100 | 17.3 | 101 | 5.8 | 17.7% | 0.64 |
| Accretion Pharmaceuticals | 215 | 22.2 | 89.6 | 9.7 | 16.7% | 0.23 |
| Walpar Nutritions | 25 | 9.9 | 78.8 | 2.5 | 8.5% | 0.89 |
| Median of the 10 others | 185 | 19.8 | 120 | 8 | 16.5% | 0.35 |
Chandra Bhagat Pharma shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little more than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders has grown a lot.
Chandra Bhagat Pharma shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 22 | Mar 23 | Sep 23 | Mar 24 | Sep 24 | Mar 25 | Sep 25 | Mar 26 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.09% | 68.24% | 68.69% | 68.77% | 69.29% | 71.20% | 72.19% | 73.02% |
| Foreign investors (FIIs) | 0.85% | 0.85% | 1.33% | 1.33% | 0.48% | 0.61% | 0.61% | - |
| Indian institutions (DIIs) | 0.00% | 0.00% | 0.89% | 0.89% | 0.00% | 0.00% | 0.00% | - |
| Number of shareholders | 126 | 146 | 134 | 152 | 315 | 316 | 301 | 280 |
Chandra Bhagat Pharma latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹90.7 cr (+316%), net profit ₹2.6 cr (+1429%) on H2 FY25.
- Shareholding, 31 March 2026: promoters 72.19% to 73.02%.
Chandra Bhagat Pharma announcements
3 on record, latest first; each opens the filing on the exchange
- Company UpdateThe Company has informed the stock exchange regarding receipt of In-Principle approval for issue of shares on preferential basisPDF ↗
- Insider Trading / SASTNotice of Closure of Trading WindowPDF ↗
- Company UpdateDisclosure under regulation 30 for resignation of Company Secretary & Compliance OfficerPDF ↗
Chandra Bhagat Pharma annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Chandra Bhagat Pharma share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Chandra Bhagat Pharma's data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- iThe shares traded on only 105 days in the past year, so the price, its range and the returns here rest on few trades.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (75,45,056 shares).
- !The FY26 results imply 80,00,000 shares at face value ₹10, which disagrees with the shareholding pattern; the pattern is used.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- !Earnings per share changes basis between FY19 (₹10.29) and FY22 (₹1.06) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
- ✓Revenue and profit are reported for every year shown, FY15 to FY26.
- iPrices run to the close on 13 Oct 2026, from the exchange's daily figures.
Questions people ask about Chandra Bhagat Pharma
What does Chandra Bhagat Pharma do?
Chandra Bhagat Pharma is an SME company listed on BSE SME, in pharmaceuticals & biotechnology.
What is the share price of Chandra Bhagat Pharma?
₹66 at the close on 19 Nov 2026, from the exchange's daily figures.
What is the market cap of Chandra Bhagat Pharma?
₹50 cr at the close on 19 Nov 2026, on 75,45,056 shares.
What is the P/E of Chandra Bhagat Pharma?
16.3 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).
What are Chandra Bhagat Pharma's revenue and profit?
Revenue ₹116 cr and profit after tax ₹3 cr in FY26.
Who are the promoters of Chandra Bhagat Pharma?
The promoter group; promoters held 73.02% at 31 March 2026.
What is Chandra Bhagat Pharma's website?
www.cbcpharma.com
More SME companies like Chandra Bhagat Pharma
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Jfl Life SciencesJFLLIFE · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2022Market cap ₹39 cr
- Onyx BiotecONYX · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2024Market cap ₹68 cr
- Medicamen OrganicsMEDIORG · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2024Market cap ₹35 cr
- Zenith DrugsZENITHDRUG · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2024Market cap ₹72 cr
- Shelter PharmaSHELTER · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹75 cr
- Vilin Bio MedVILINBIO · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹78 cr
Every listed SME company in Pharmaceuticals & Biotechnology →
Built from 3 exchange announcements, 8 shareholding patterns and 12 years of reported results. Every figure carries its source; where the documents are silent, the page says so.